Fluoxetine, Smoking, and History of Major Depression: A Randomized Controlled Trial by Spring, Bonnie et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Faculty Publications, Department of Psychology Psychology, Department of 
11-1-2007 
Fluoxetine, Smoking, and History of Major Depression: A 
Randomized Controlled Trial 
Bonnie Spring 
University of Illinois at Chicago 
Neal Doran 
University of Illinois at Chicago 
Sherry Pagoto 
University of Illinois at Chicago 
Dennis E. McChargue 
University of Nebraska-Lincoln, dmcchargue2@unl.edu 
Jessica Werth Cook 
University of Illinois at Chicago, jwcook@ctri.wisc.edu 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unl.edu/psychfacpub 
 Part of the Psychiatry and Psychology Commons 
Spring, Bonnie; Doran, Neal; Pagoto, Sherry; McChargue, Dennis E.; Werth Cook, Jessica; Bailey, Katherine; 
Crayton, John; and Hedecker, Donald, "Fluoxetine, Smoking, and History of Major Depression: A 
Randomized Controlled Trial" (2007). Faculty Publications, Department of Psychology. 280. 
https://digitalcommons.unl.edu/psychfacpub/280 
This Article is brought to you for free and open access by the Psychology, Department of at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Faculty Publications, 
Department of Psychology by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Authors 
Bonnie Spring, Neal Doran, Sherry Pagoto, Dennis E. McChargue, Jessica Werth Cook, Katherine Bailey, 
John Crayton, and Donald Hedecker 
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
psychfacpub/280 
Journal of Con~ulting and Clin~cal Psychology 
2007, Vol. 75. No. 1, 85-94 
Fluoxetine, Smoking, and History of Major Depression: 
A Randomized Controlled Trial 
Bonnie Spring 
University of Illinois at Chicago, Edward Hines Jr. Veterans 
Affairs Hospital, and Northwestern University 
Sherry Pagoto and Dennis McChargue 
University of Illinois at Chicago and Edward Hines Jr. Veterans 
Affairs Hospital 
John Crayton 
Edward Hines Jr. Veterans Affairs Hospital 
Neal Doran 
University of Illinois at Chicago 
Jessica Werth Cook and Katherine Bailey 
University of Illinois at Chicago 
Donald Hedeker 
University of Illinois at Chicago 
The study was a randomized placebo-controlled trial testing whether fluoxetine selectively enhances 
cessation for smokers with a history of depression. Euthymic smokers with (H+, n = 109) or without 
(H-, n = 138) a history of major depression received 60 mg fluoxetine or placebo plus group behavioral 
quit-smoking treatment for 12 weeks. Fluoxetine initially enhanced cessation for H +  smokers ( p  = .02) 
but subsequently impaired cessation regardless of depressive history. Six months after quit date, 
fluoxetine-treated participants were 3.3 times more likely to be smoking ( p  = .02). Further research is 
warranted to determine why high-dose fluoxetine produces continuing effects that oppose tobacco 
abstinence. 
Keywords: tobacco, smoking cessation, depression, fluoxetine, randomized controlled trial 
Serotonergic agents have been found generally ineffective for 
enhancing long-term (> 6 months) tobacco abstinence (Hughes, 
Stead, & Lancaster, 2005). More favorable short-term results have 
emerged in some trials (Bowen, Spring, & Fox, 1991; Cornelius, 
Perkins, Salloum, Thase, & Moss, 1999; Killen et al., 2000; Niaura 
et al., 2002; Spring et al., 1995; Spring, Wurtman, Gleason, Wurt- 
man, & Kessler, 1991) but not others (Blondal et al., 1999; Covey, 
Glassman, Stetner, Rivelli, & Stage, 2002; Naranjo, Kadlec, San- 
hueza, Woodley-Remus, & Sellers, 1990; Saules et al., 2004; 
Sellers, Naranjo, & Kadlec, 1987). Variability in outcome for 
fluoxetine might be explained if the drug has a selective effect, 
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primarily benefiting the many current smokers who are depression 
prone. A drug benefit for cessation might emerge chiefly in studies 
that included a high proportion of smokers with (H+) versus 
without (H-) a history of major depressive disorder (MDD). Other 
pharmacotherapies for smoking (bupropion and nortriptyline) have 
not shown differential efficacy for euthymic H+ versus H- smok- 
ers (Hughes et al., 2005). However, to our knowledge, no previ- 
ously reported studies had been conducted to examine whether, as 
cessation aids, serotonergic agents selectively benefit smokers 
with a history of depression. 
The influence of MDD history on cessation failure remains 
controversial (Covey, 2004; Hitsman, Borrelli, McChargue, 
Spring, & Niaura, 2003; Hitsman, Spring, Borrelli, McChargue, & 
Niaura, 2004). Pre-quit dysphoria (Hall, Munoz, & Reus, 1994; 
Killen et al., 1996; Rausch, Nichinson, Lamke, & Matloff, 1990; 
Swan, Ward, & Jack, 1996) and postquit depressive symptoms 
(Covey, Glassman, & Stetner, 1990; Killen, Fortmann, Schatzberg, 
Hayward, & Varady, 2003) have both been shown to predict 
relapse. Both are characteristic of H+ smokers (Borrelli et al., 
1999; Hitsman et al., 2003; Pomerleau et al., 2004). Fluoxetine 
might plausibly benefit H+ smokers because it has been shown to 
reduce their depressive symptoms prior to a quit attempt (Dalack, 
Glassman, Rivelli, Covey, & Stetner, 1995) and to improve short- 
term abstinence (Hitsman et al., 1999; Blondal et al., 1999) among 
smokers who have elevated baseline depression but are subthresh- 
old for MDD. Also, the drug displays increased efficacy relative to 
placebo as a cessation aid for smokers who exhibit mild pre-quit 
symptoms of depression (Blondal et al., 1999; Hitsman et al., 
1999). Fluoxetine might especially benefit H+ smokers in the time 
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frame shortly after quitting, when they exhibit heightened postquit 
mood disturbance (Hall et al., 1994) and increased risk of relapse 
into a depressive episode (Borrelli et al., 1996; Glassman, 1997; 
Killen et a]., 2003; Tsoh et al., 2000). 
Consequently, this double-blind, randomized, placebo- 
controlled clinical trial tested the effect of 60 mg fluoxetine plus 
cognitive-behavioral smoking cessation treatment on abstinence 
among euthymic H+ and H- smokers. We hypothesized that H +  
smokers would show superior abstinence when treated with flu- 
oxetine, whereas no drug effect would be evident for H- smokers. 
Method 
Recruitment and Entry Criteria 
Interested smokers were recruited by newspaper and radio ad- 
vertisements; screened initially via telephone; then mailed ques- 
tionnaires about demographics, medical history, tobacco use 
(Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991), alcohol 
use (Selzer, 1973), and depression (Beck, Steer, & Brown, 1996). 
They returned these in person, provided informed consent, and 
were interviewed with the Hamilton Depression Rating Scale 
(Ham-D; Hamilton, 1960) and the Structured Clinical Interview 
for DSM-IV (SCID-IV), Non-Patient Version (Spitzer, Williams, 
& Gibbon, 1994; First, Gibbon, Spitzer, & Williams, 1996). As- 
sessors were master's- and doctoral-level psychology trainees un- 
der the supervision of the principal investigator, a licensed, board- 
certified clinical psychologist. They received 11 hours of 
standardized videotape training on the SCID-IV (First et al., 
1996). Then they conducted mock interviews, observed patient 
interviews conducted by an experienced assessor, and were ob- 
served during live interviews until they attained 100% interrater 
reliability on MDD symptoms and diagnosis. Throughout the 
study, all assessors attended weekly supervision meetings with the 
principal investigator to discuss each case. Diagnostic disagree- 
ments were resolved by consensus. 
At a second screening visit, the study physician assessed exclu- 
sionary medical conditions. Entry criteria specified males or fe- 
males ages 18-65 who smoked at least 10 cigarettes per day for 
the past year. They could be categorized either as lacking a lifetime 
history of MDD or as having at least one past episode of MDD. 
Participants could not be currently depressed, as evidenced by a 
Beck Depression Inventory (BDI) score > 15, a Ham-D score > 
14, or an MDD episode within the past 6 months. Also ineligible 
were those meeting criteria for any current episode of Axis I 
disorder (other than nicotine dependence) assessed by the SCID, or 
having a history of seizures, psychosis, or bipolar disorder. Addi- 
tional exclusion criteria were current use of nicotine replacement 
therapy, beta blockers, thiazide diuretics, guanethidine, reserpine, 
- 
clonidine, Type IC antiarrhythmics, or highly protein-bound drugs; 
or use of psychotropic medication within the past month. Also 
screened out were those with medically unstable conditions, CBC 
values 10% outside normal limits, liver enzymes exceeding 40% of 
the upper limit of normal, severe allergies, or allergy to fluoxetine; 
and women who were pregnant, lactating, or trying to become 
pregnant. 
The Institutional Review Boards of the University of Illinois at 
Chicago and Edward Hines Jr. Veterans Affairs Hospital provided 
ethical approval for the study. 
Study Design and Participant Flow 
Of 2,050 candidates, 247 were eligible (Figure 1). The main 
factors that resulted in failure to meet entry criteria were exclu- 
sionary medications (45.2% of ineligible candidates), unstable 
medical condition (17.4%), age (13.6%), smoking < 10 cigarettes1 
day (1 1.3%), and psychological disorder (4.2%). The study phar- 
macist stratified participants by depression history and used 
computer-generated random numbers to assign them to drug or 
placebo. Research staff and participants were blinded to medica- 
tion status. Medications were distributed at each treatment visit, 
including the first. Treatment groups met nine times during the 
12-week treatment: weekly for 6 weeks and bi-weekly thereafter. 
Assigned quit date was the evening prior to the fourth visit. Thus, 
there were three visits before and six after the scheduled quit. 
BDI data were collected at baseline; on the target quit date; and 
at 4, 8, 16, and 24 weeks postquit. Participants completed the 
Ham-D at baseline; on quit day; and at 4, 8, 12, 16, 20, and 24 
weeks after the quit day. Blood and urine samples, collected 1 and 
8 weeks postquit, were assayed to assess medication adherence. 
Following treatment, participants attended four paid ($lO/visit) 
monthly follow-up visits. 
Intervention Through Cognitive-Behavioral Cessation 
Treatment 
Manualized group treatment incorporated cognitive- behavioral 
and motivational interviewing techniques (Spring, 2002, in press). 
Treatment after quit date focused on coping with cravings, pre- 
venting relapse, and recycling relapsed participants toward another 
quit attempt. 
Phamzacotherapy 
At each visit, fluoxetine (D+) and placebo (D-) were dispensed in 
identical capsules and unused medication was returned. Additional 
pills, to be taken with each drug dose, were also prescribed to all 
participants. These pills, described as containing a cofactor necessary 
for making the medication work, actually supplied a 50-mg riboflavin 
tracer detectable in urine, enabling assessment of medication adher- 
ence for both placebo and drug. Drug dosage increased gradually over 
2 weeks: 20 mg for 4 days; then 30 mg for 3 days, 40 mg for 3 days, 
50 mg for 5 days, and 60 mg for the remainder of the treatment. 
Treatment group leaders elicited information about side effects at each 
group session and were available by pager between sessions to ad- 
dress clinical concerns. The study physician delayed an increased or 
lowered dosage for participants reporting severe side effects. Drug 
was discontinued abruptly at the end of the treatment phase. 
Measures 
Point prevalence abstinence was determined for each visit 
through the end of follow-up. Smoking status was assessed by 
self-report, expired carbon monoxide (CO), and salivary cotinine. 
CO was measured at all visits; cotinine samples were collected at 
4 and 8 weeks postquit, and at the 4- and 6-month postquit 
follow-ups. Participants were considered smoking if they self- 
reported any smoking since the prior visit, had CO value > 10 
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Figure I .  Participant flow through the trial. Participants were considered to have completed treatment if they 
attended at least one of the final two treatment visits, and to have completed follow-up if they attended at least 
one of the final two follow-up visits. 
parts per million, or had cotinine value r 20 nglml. Prolonged Statistical Analyses 
abstinence was coded as continuous abstinence from a grace 
period ending 2 weeks after quit date (Hughes et al., 2003) through 
end of treatment or end of follow-up. 
When participants could not attend a session, they self-reported 
smoking status by telephone. To appraise the validity of self- 
report-only smoking status, we examined concordance between 
self-report and bioverification for each participant. Of the 181 
participants who self-reported only abstinence, 15 had their data 
recoded as smoking because their self-reported abstinence at an- 
other timepoint was contradicted by CO or cotinine. What we 
judged to be dishonest claims of abstinence did not vary by drug, 
but varied by depression history, X2(1) = 3 . 8 9 , ~  = .049: 12 out of 
15 dishonest reporters were MDD-history negative. 
We measured pill-taking adherence for both treatment groups by 
grading urine samples according to riboflavin fluorescence (Kapur, 
1992). Plasma fluoxetine and norfluoxetine levels for drug-treated 
participants were measured using gas-liquid chromatography 
(Nash, Bopp, Carmichael, Farid, & Lemberger, 1982). 
Smoking status (abstinent vs. smoking) was measured at mul- 
tiple time points from 2 weeks to 6 months postquit. Power was 
estimated using Hsieh's formula (Hsieh, 1988) for dichotomous 
data over time. Based on the primary study hypothesis, the study 
was powered to detect a clinically meaningful drug effect on 
abstinence, if one was present, for H+ smokers and for H- 
smokers separately. Specifically, the study was powered to detect 
a 20% difference in abstinence between drug and placebo, sepa- 
rately for H+ and H- smokers, with power set at .80 and a 
two-sided alpha of .05. The assumed abstinence rate for the pla- 
cebo group was set between 0 and 10% for H+ smokers and 
between 20 and 30% for H- smokers. The sample sizes of H +  and 
H- smokers were set so as to ensure that the drug versus placebo 
comparison had power of at least .80 for a 20% drug benefit, under 
any of these placebo base rates. Sample acquisition was discon- 
tinued when analyses conducted after accrual of the H+ sample 
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showed a negative drug effect on long-term abstinence in both 
history groups. 
Data were analyzed by intent-to-treat: All randomized partici- 
pants were included in the analyses under their original group 
assignments. Smoking status at eight time points (Postquit Weeks 
2, 4, 6, and 8 of treatment, and follow-up visits 3, 4, 5, and 6 
months after the quit date) was analyzed longitudinally using 
logistic regression for correlated dichotomous responses estimated 
by the generalized estimating equations (GEE) method (Liang & 
Zeger, 1986), implemented via SAS PROC GENMOD. The GEE 
method uses all available data to estimate model parameters, rather 
than excluding cases with missing data or requiring deterministic 
imputations (e.g., missing data are equivalent to smoking). With 
GEE, it is assumed that the missing data are random, after adjust- 
ing for model covariates. For example, if missing data increase 
across time, but are unrelated to variables other than time, and time 
is included as a model covariate, then the GEE assumption is 
reasonable. To better account for the missing data and satisfy this 
assumption that missingness is random after adjusting for covari- 
ates, the model included the following covariates: weeks until 
dropout (the visit after which no further smoking data were ob- 
tained), percentage rate of attendance for visits prior to dropout, 
and percentage of missed visits where smoking was reported by 
telephone. Finally, GEE models are robust to misspecification of 
the dependency structure that results from repeated assessments of 
an individual over time (Diggle, Heagerty, Liang, & Zeger, 2002). 
We chose an m-dependent (Toeplitz) correlation structure based 
on the observed correlations of smoking status across time. 
The GEE model characterized the repeated dichotomous classi- 
fications in terms of initial (Postquit Week 2) cessation and time- 
related changes in cessation. All analyses included time and time- 
squared terms to allow for curvilinear trends in cessation across 
time. Tests determined the effects of drug (fluoxetine vs. placebo), 
depression history (present vs. absent), and their interactions with 
each other and with time. Nonsignificant interaction terms were 
removed from the model in a backwards manner (i.e., three-way 
interactions first, followed by two-way and then main effects; 
Drug X Time-Squared first, then Drug X Time), and the model 
was refitted. Full sample analysis was followed by planned strat- 
ified analyses within each history group, and by per protocol 
analyses that considered only treatment-adherent participants. 
Moderator analyses tested whether drug and history effects varied 
Table 1 
Characteristics by Group 
by gender. For comparability with other trials of smoking medi- 
cations, we also analyzed prolonged abstinence at end of treatment 
and end of follow-up via binary logistic regression, assuming that 
all missing data signified smoking. Finally, the effects of drug and 
history on symptoms of depression over time were assessed, in a 
manner analogous to the longitudinal analysis of smoking, with 
mixed-effects regression models for continuous variables (Ver- 
beke & Molenberghs, 2000). 
Results 
Participant Characteristics 
Participants (N = 247; 54% female) were 62% Caucasian, 26% 
African American, 4% Latino, 3% Asian, 5% multiethnic (Table 
1). Groups did not differ with respect to age, race, cigarettes 
smoked per day, nicotine dependence, baseline depression, weeks 
until dropout, percentage of visits attended, or percentage of 
missed visits at which participants reported smoking status by 
telephone. A marginal difference in sex distribution, X2(1) = 3.12, 
p = .08, suggested that H+ smokers (60%) were more likely than 
H- smokers (50%) to be female. Of the 44% of study participants 
who reported a history of MDD, 30% reported multiple episodes. 
Smoking Outcome 
Table 2 shows all covariate, history, and drug main effects, and 
statistically significant interactions in the GEE analysis predicting 
smoking status for the full sample. Here we note only significant 
findings. Overall, the probability of smoking increased across time 
in a curvilinear manner. Participants who dropped out earlier were 
more likely to be smoking. Also, greater nicotine dependence 
predicted an increased likelihood of smoking. 
In regard to the main study question, the a priori analyses 
partially supported the primary hypotheses. Planned GEE analyses 
stratified by depression history yielded a Drug X Time interaction 
among H+ smokers (z = 2.14, p = ,032, Figure 2). Supplemental 
GEE analyses stratified by history and study period (treatment vs. 
follow-up) showed that for H+ smokers, fluoxetine, relative to 
placebo, enhanced abstinence during the treatment period, z = 
-2.27, odds ratio [OR] = 0.28 (.09, .84), p = .023. During 
follow-up after treatment, however, fluoxetine impaired absti- 
Characteristic 
History - placebo History - fluoxetine History + placebo History + fluoxetine 
(n = 72) (n = 66) (n = 51) (n = 58) 
Age (years) 
Sex (no. and % female) 
Race (no. and % White) 
Cigarettes per day 
FTND score 
BDI score 
Weeks until dropout 
Attendance at visits predropout 
Missed visits, smoking reported by telephone 
Note. FTND = Fagerstrom Test for Nicotine Dependence; BDI = Beck Depression Inventory. 
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Table 2 
Generalized Estimating Equations (GEE) Model Predicting Smoking Status 
Regression 95% confidence 
Variable coefficient SE z interval 
Covariates 
FTND score 0.16 0.07 2.17* 0.21, 4.13 
Weeks until dropout 
-0.10 0.02 -5.23** -7.20, -3.28 
Attendance pre-dropout - 1.43 1.43 - 1 .OO -2.96, 0.96 
Smoking status called in 0.09 0.42 0.21 -1.75, 2.17 
Gender -0.13 0.28 -0.46 -2.42, 1.50 
Time effects 
Time 0.32 0.15 2.10' 0.14, 4.06 
Timez -0.05 0.02 - 2.42" -4.38, -0.46 
Group and Group X Time effects 
Depression History 0.12 0.3 1 0.38 - 1.58, 2.34 
Depression History X Time -0.27 0.21 -1.24 -3.20, 0.72 
Depression History X Time2 0.07 0.03 2.03* 0.07, 3.98 
Drug -0.13 0.30 -0.43 -2.39, 1.53 
Drug X Time 0.16 0.07 2.24' 0.28, 4.19 
Note. 0 = abstinent, 1 = smoking. FIND = Fagerstrom Test for Nicotine Dependence. 
* p  < .05. * * p  < .01. 
nence, z = 2.95, OR = 7.00 (1.99,24.70), p = .003 (Figure 2). For ticipant's having been treated with fluoxetine predicted increased 
H- smokers, fluoxetine effects were nonsignificant but direction- risk of smoking during follow-up (Figure 3). Assuming missing 
ally negative. data = smoking did not alter these results. Supplementary logistic 
Analysis of the full sample also yielded a Drug X Linear Time regression analyses showed that at end of treatment (i.e., postquit 
interaction (z = 2.24, p = ,025). Drug had no significant effect on Week 8 in Figure 3), drug did not significantly affect smoking 
abstinence during the treatment period; but, subsequently, a par- status (z = 1.58, OR = 2.02, p = ,114). However, at end of 
History Positive 
-a- Fluoxetine 
---*---  Placebo 
0 2 4 6 8 10 12 14 16 18 20 22 24 26 0 2 4 6 8 10 12 14 16 18 20 22 24 26 
Weeks after quit Weeks after quit 
Figure 2. Abstinence rates by drug status for those with a history of depression (left panel) and for those with 
no history of depression (right panel). Shading indicates on-drug phase (available data). 
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0 2 4 6 8 10 12 14 16 18 20 22 24 26 
Weeks after quit 
Figure 3. Abstinence rates by drug status for complete sample using all 
available data. Shading indicates on-drug phase. 
follow-up (i.e., 6 months postquit in Figure 3), participants previ- 
ously treated with fluoxetine were 3.3 times more likely to be 
smoking, z = 2.32, OR = 3.33 (1.21, 9.20), p = .020. 
Additionally, the GEE full sample analysis yielded a Depression 
History X Quadratic Time interaction ( z  = 2.03, p = .043, Figure 
4). During the treatment phase, H- smokers, in comparison to H+ 
smokers, showed an initial marginal cessation advantage that re- 
versed over time (z = -1.94, p = ,052). During follow-up, they 
showed an initial relative cessation advantage that tended to in- 
crease (z = 1.72, p = ,086). Stated differently, H+ showed a 
relative cessation disadvantage 2 weeks postquit, followed by a 
cessation advantage during the remainder of treatment. Then, 
during follow-up, H+ consistently showed worse cessation than 
H-, and their disadvantage increased across time. 
Logistic regression analyses of prolonged abstinence showed no 
Time interactions in opposite directions for both men ( z  = -2.28, 
p = ,023) and women ( z  = 2.53, p = .012). For women, the 
disproportionate negative effect of depression history on absti- 
nence increased progressively over time. By 6 months postquit, 
H+ women were nearly 3 times more likely to be smoking than 
H- women (z = 2.21, OR = 2.86, p = .027). H+ males were also 
disadvantaged relative to H-, but the differences decreased over 
time and were nonsignificant during follow-up. 
Blinding. When asked to guess drug assignment after 3 weeks 
of treatment (i.e., 1 week before the quit date), neither participants' 
accuracy, x2(1) = 0.47, p = ,493, nor facilitators' accuracy, 
x2(1) = 1 . 4 6 , ~  = .23, varied by treatment group. Drug assignment 
was guessed correctly by 59.8% of placebo and 64.6% of fluox- 
etine participants. Facilitators guessed correctly for 65.3% of pla- 
cebo and 55.6% of fluoxetine participants. Participants' accuracy 
did not predict smoking status over time ( z  = 0.1 1, p = .9 12) but 
was greater than chance for both participant guesses, x2(1) = 
11.22, p = ,0008, and facilitator guesses, ~ ' ( 1 )  = 9.42, p = .002. 
Medication adherence. Freezer malfunction caused some loss 
of urine and plasma samples. Urine samples were available from 
73 placebo and 71 fluoxetine participants 1 week after the quit 
date, and from 41 placebo and 46 fluoxetine participants at 8 
weeks postquit. Plasma samples were available from 65 and 39 
fluoxetine participants at Postquit Weeks 1 and 8, respectively. 
Riboflavin analyses collapsed across drug showed 83.3% com- 
pliance at Week 1 and 79.3% at Week 8. Adherence varied by drug 
group at Week 1, x2(1) = 5.34, p = ,021: More placebo partici- 
pants (90.4%) than fluoxetine participants (76.1%) were compli- 
ant. The drug groups no longer differed at Week 8, X 2 ( 1 )  = 0.07, 
p = .798: 80.5% of placebo and 78.3% of fluoxetine patients were 
adherent. 
For the drug group, fluoxetine and norfluoxetine values were 
added and log-transformed to create a single outcome variable. 
Mixed effects regression modeling showed that metabolite level 
did not vary by time, nicotine dependence, history of depression, 
attendance, or time until dropout. Metabolite level was positively 
significant effects of history, drug or their interaction. Equating 
missing data to smoking yielded an overall end-of-treatment pro- 
longed abstinence rate of 21.1% (521247): H- D- 20.8% (15172); 
H+ D- 21.6% (11151); H- D+ 16.7% (11166); H+ D+ 25.9% 
(15158). The comparable end-of-follow-up prolonged abstinence 
rate was 10.5% (261247): H- D- 13.9% (10172); H+ D- 9.8% 
(5151); H- D+ 7.6% (5166); H+ D+ 10.3% (6158). 
Treatment Moderators and Processes 
Gender. Our GEE analysis explored whether the effects of 
drug and depression history were comparable for both genders 
(Table 3). Results showing a significant Gender X Drug X Linear 
Time interaction (z = -2.38, p = .017) were interpreted by 
stratifying the sample on gender and testing the separate interac- 
tive effects of drug assignment with time. The Drug X Linear 
Time interaction was significant for men (z  = 3.32, p = ,001) but 2 4 6 8 10 12 14 16 18 20 22 24 26 
not women (z = 0.22, p = ,829). B y  final follow-up, men previ- 
ously treated with fluoxetine were more than 4 times as likely to be Weeks after quit 
smoking as placebo-treated men ( z  = 2.19, OR = 4.17, p = ,028). 
Moderator analysis also rewaled a significant Gender x De- Figure 4. Abstinence rates by history of depression (availa61e data). 
pressive History X Linear Time interaction (z = 2.60, p = ,009). Shading indicates on-drug phase. H+ = history of depression; H- = no 
Stratifying the sample by gender yielded significant History X history of depression. 
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Table 3 
Generalized Estimating Equations (GEE) Moderator Analysis Predicting Smoking Status 
Including Gender Interaction Terms 
Regression 95% confidence 
Variable coefficient SE z interval 
Covariates 
m N D  score 0.14 0.07 1.99' 0.03, 3.95 
Weeks until dropout -0.11 0.02 -5.40** -7.38, -3.46 
Attendance predropout - 1.40 1.41 -0.99 -2.94, 0.98 
Smoking status called in 0.10 0.41 0.23 -1.75, 2.17 
Gender -0.05 0.50 -0.11 - 1.89, 2.03 
Time effects 
Time 0.28 0.15 1.84 0.08, 4.00 
Time2 -0.05 0.02 -2.06* -3.94, -0.02 
Group and Group X Time effects 
Depression History 0.62 0.45 1.39 -0.53, 3.39 
Depression History X Time -0.51 0.22 -2.31' -4.34, -0.42 
Depression History X Time2 0.06 0.03 1.98' -0.07, 3.85 
Drug -0.47 0.44 - 1.07 -2.92, 1.00 
Drug X Time 0.44 0.12 3.73** 1 .SO, 5.42 
Gender interaction effects 
Gender X Time -0.06 0.12 -0.47 -2.43, 1.49 
Gender X History -0.84 0.58 - 1.44 -3.40, 0.52 
Gender X History X Time 0.41 0.16 2.60*' 0.64, 4.56 
Gender X Drug 0.46 0.58 0.79 -1.17, 2.75 
Gender X Drug X Time -0.37 0.16 -2.38* -4.35, -0.42 
Note. 0 = abstinent, 1 = smoking. FTND = Fagerstrom Test for Nicotine Dependence. 
* p  < .05. * * p  < .01. 
associated with riboflavin compliance, F( l ,  67) = 7.61, p = ,008. 
At the 1st week postquit, the mean fluoxetine + norfluoxetine 
blood level was 427.95 nglml, SD = 352.62 (men: M = 392.10, 
SD = 371.28; women: M = 457.03, SD = 339.08). Eight weeks 
after the quit date, the mean level was 412.78 (SD = 348.90; men: 
M = 397.02, SD = 320.84; women: M = 420.00, SD = 367.45). 
Values were comparable to average fluoxetine + norfluoxetine 
blood level reported elsewhere (60 mg = 421.95; Koran, Cain, 
Dominguez, Rush, & Thiemann, 1996). 
Per protocol artalysis. In this study, 155 participants were 
adherent with behavioral treatment, operationalized as having at- 
tended six of the nine treatment sessions. The Drug X Linear Time 
interaction remained significant in the adherent subsample ( z  = 
2.27, p = .023). Again, fluoxetine produced a negative effect on 
abstinence that increased over time. Although the Depression 
History X Quadratic Time interaction became marginal ( z  = 1.92, 
p = .055), its direction again suggested that H+ smokers were 
initially less and subsequently more likely to be smoking. 
For participants randomized to placebo, medication compliance 
was operationalized as all assays having tested positive for ribo- 
flavin and no assays having tested nonzero for fluoxetine or 
norfluoxetine. For those randomized to fluoxetine, compliance was 
defined as all assays having tested positive for riboflavin and for 
nonzero values of fluoxetine and norfluoxetine. We found 72% 
(n = 88) of placebo and 80% (n  = 99) of fluoxetine participants 
to be medication compliant. GEE analysis of the adherent sub- 
sample replicated the significant interactions found using all avail- 
able data: Drug X Linear Time ( z  = 2.51, p = ,012); History X 
Quadratic Time ( z  = 2.17, p = ,030). 
Depressive symptoms. Random effects regression modeling of 
BDI and Ham-D data over time indicated that H+ smokers had 
higher Ham-D scores than H- smokers at baseline, and the differ- 
ence persisted throughout the treatment and follow-up periods, 
t(667) = 4 . 0 6 , ~  = ,001. Similarly, H+ smokers had elevated BDI 
scores at baseline, but there was a significant Depression His- 
tory X Linear Time interaction indicating that the difference 
diminished somewhat over time, t(500) = -2.62, p = ,009. Flu- 
oxetine treatment had no effect on either BDI scores, t(500) = 
0.70, p = ,486, or Ham-D scores, t(667) = 1.38, p = .168. There 
was also no evidence that discontinuing fluoxetine increased de- 
pressive symptoms. 
Clinical significance. To evaluate whether fluoxetine's negative 
long-term effect on abstinence was clinically significant, we calcu- 
lated number needed to harm (NNH) (Kraemer & Kupfer, 2006; 
McQuay & Moore, 1997). At the end of the follow-up phase, NNH 
for the drug effect was 5 (95% confidence interval 40, 3), indicating 
a clinically meaningful adverse drug effect. An NNH of 5 means that 
if 5 patients were treated with fluoxetine, 1 would be more likely to 
be smoking at end of follow-up than if all had received placebo. To 
evaluate whether fluoxetine's initial enhancement of cessation among 
H+ smokers was clinically meaningful, we calculated number needed 
to treat (NNT). Six weeks after quit date, NNT for H+ smokers 
treated with fluoxetine was 13, meaning that 13 H+ smokers would 
need to be treated with fluoxetine in order to produce 1 case of 
abstinence not seen with placebo treatment. However, by 8 weeks 
after quit date, when treatment ended, there was no longer a drug 
benefit, but rather there was an NNH of 44. Thus, there was not 
evidence of a clinically important, sustained, short-term benefit of 
fluoxetine for smokers with a history of depression. 
Discussion 
We tested whether fluoxetine selectively aids smoking cessation 
for H+ smokers, relative to H- smokers. As predicted, fluoxetine, 
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compared to placebo, improved initial cessation outcome for H+ 
but not H- smokers during most of the period through which 
smokers remained in treatment. Regardless of depression history, 
however, smokers treated with fluoxetine were more likely to be 
smoking during follow-up. Six months postquit, formerly 
fluoxetine-treated participants were 3.3 times more likely to be 
smoking than formerly placebo-treated participants. 
Our finding of an initial drug benefit confined to H+ smokers is 
consistent with other observations of a short-term improvement in 
abstinence due to fluoxetine among H+ smokers (cf. Cornelius, 
Perkins, Salloum, Thase, & Moss, 1999). Results also resemble 
other prior findings showing a short-term benefit of fluoxetine for 
smokers who show some depressive symptoms (Blondal et al., 
1999; Hitsman et al., 1999). The drug benefit we observed for H+ 
smokers was only short-term. It lasted for much of the 2-month 
period that immediately followed the quit date (during which 
participants remained on medication), but it had dissipated by the 
end of treatment. 
We expected that a beneficial effect of fluoxetine on H+ absti- 
nence would be mediated by an antidepressant action of fluoxetine 
at baseline or during the immediate postquit period. However, no 
drug effect on depressive symptoms was observed, nor were there 
interactions between drug, time, and depressive history. Hence, we 
cannot attribute fluoxetine's transient cessation advantage for H+ 
smokers to an alleviation of depressive symptoms. We have in- 
sufficient data on other nicotine withdrawal symptoms to comment 
on whether drug effects on withdrawal might offer an alternative 
explanation. 
Having a history of depression and exhibiting pre- or postquit 
depressive symptoms are individual differences that tend to co- 
occur (Borrelli et al., 1999; Hitsman et al., 2003; Pomerleau et al., 
2004). This constellation of attributes may signify the presence of 
an underlying vulnerability to depression that accompanies height- 
ened sensitivity to serotonergic intervention. In the current study, 
depressive vulnerability, indexed by a participant's having a his- 
tory of MDD, predicted heightened positive responsiveness (albeit 
on a short-lived basis) to a serotonin-enhancing drug. In a differ- 
ent, opposite intervention context, we found that having a history 
of depression plus being a smoker predicted heightened negative 
responsiveness to a tryptophan-depleting dietary challenge that 
transiently lowers serotonin (Spring et al., 2007). Variation in the 
degree to which smokers vulnerable to depression are represented 
in study samples may help to explain inconsistent short-term 
findings from trials testing serotonergic agents as cessation aids. 
Fluoxetine's more long-lasting and more clinically important 
influence was a negative effect on cessation. A negative effect on 
abstinence has been observed in three prior fluoxetine studies 
(Naranjo et al., 1990; Niaura et al., 2002; Spring et al., 1995). 
Current results parallel the findings of Covey et al. (2002) from a 
trial of the selective serotonin reuptake inhibitor (SSRI) sertraline 
for H+ smokers. Although neither effect was significant in that 
study, Covey et al. (2002) reported the pattern observed in the 
current study: increased abstinence associated with SSRI treatment 
while on medication, reversing to reduced abstinence during 
follow-up. 
The reversal of a fluoxetine-related abstinence advantage for 
H+ smokers began toward the end of treatment and continued 
throughout follow-up. That transition from a beneficial to a detri- 
mental drug effect warrants comment, as does the drug's more 
consistently adverse effect on cessation for H- smokers. We con- 
sidered two mechanisms that might explain the negative effect: 
one related to a fluoxetine discontinuation syndrome and the other 
related to neurobiological changes triggered by chronic fluoxetine 
exposure. Consistent with other evidence that fluoxetine's slow 
clearance from the body precludes a discontinuation syndrome 
(Judge, Parry, Quail, & Jacobson, 2002), smokers in this study did 
not report fluoxetine withdrawal symptoms. Fluoxetine lacked an 
effect on depressive symptoms during follow-up, just as it had 
during treatment. Thus, fluoxetine's negative effect on abstinence 
among H+ smokers during the follow-up period does not appear 
to reflect a fluoxetine discontinuation syndrome. 
An alternative, biological explanation of the negative drug effect 
derives from animal studies showing that chronic fluoxetine use 
suppresses dopamine (DA) in the nucleus accumbens system, 
which modulates reward (Ichikawa, Kuroki, & Meltzer, 1998; 
Ichikawa & Meltzer, 1995; Korsgaard, Gerlach, & Christensson, 
1985). Nicotine's rewarding effects are partially mediated through 
activation of DA release in the nucleus accumbens (Corrigall, 
1991; Gamberino & Gold, 1999). Conversely, removal of nicotine 
suppresses dopaminergic neurotransmission and elevates brain re- 
ward threshold, signifying decreased reward sensitivity or anhe- 
donia (Epping-Jordan, Watkins, Koob, & Markou, 1998; Harrison, 
Liem & Markou, 2001; Markou, Kosten, & Koob, 1998). Although 
coadministration of fluoxetine in the short-term prevents this re- 
ward decrement (Hamson et al., 2001), continuing to administer 
fluoxetine chronically, as was done in the current study, decreases 
extracellular DA in the nucleus accumbens (Ichikawa et al., 1998; 
Ichikawa & Meltzer, 1995; Korsgaard et al., 1985). 
To the extent that these animal data can be extrapolated to 
humans, chronic fluoxetine administration may augment a func- 
tional DA deficiency state already triggered by nicotine depriva- 
tion. Consequently, drug-treated smokers in the present study may 
have found cigarettes increasingly tempting. They may have re- 
sumed smoking in order to restore reward functioning. The obser- 
vation that abstinence began to decline for fluoxetine-treated cases 
even before drug treatment ended is consistent with the possibility 
that chronic fluoxetine treatment heightened the reward value of 
nicotine. That fluoxetine's adverse effect on abstinence continued, 
and among H+ smokers worsened, after the drug was discontinued 
might reflect progressive central nervous system adaptation to 
fluoxetine withdrawal. However, it is also plausible that neuro- 
physiological changes undermining abstinence were initiated dur- 
ing drug exposure, developed gradually, and became evident clin- 
ically only after an incubation phase that just happened to conclude 
after drug treatment ended. The present study was not designed to 
distinguish between these two scenarios experimentally, and they 
are very challenging to differentiate analytically after the fact. 
Relevant interpretive issues have been discussed recently in the 
context of late-appearing serious thrombotic events that became 
evident after rofecoxib (Vioxx) discontinuation, leading to the 
drug's withdrawal from the market (Lagakos, 2006). 
We also observed two post hoc moderator effects related to 
gender. One suggested that the adverse effect of fluoxetine on 
abstinence was heightened for men. The other suggested that a 
negative effect on abstinence of a history of depression grew 
stronger over time for women. Because we made no gender-related 
predictions for this study, both moderator effects were unantici- 
pated. Those findings would need to be replicated by others before 
being considered meaningful. 
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Our findings have some limitations. First, as is typical of smok- 
ing cessation trials (Ahluwalia, Harris, Catley, Okuyemi, & Mayo, 
2002; Jorenby et al., 1999), study attrition was substantial: 63- 
78% completed treatment; 55-67% completed follow-up. Second, 
as is customary for an efficacy trial, the sample was highly 
selected, which may limit generalizability. Approximately 12% of 
those who expressed interest were randomized, comparable to the 
9% randomized in other studies of antidepressant pharmacother- 
apy plus behavioral cessation counseling (Hall et al., 2002; Hall, 
Humfleet, Reus, Munoz & Cullen, 2004). Third, we were only 
partially successful in keeping the study blind. Facilitators and 
patients were not very successful at guessing their drug assign- 
ments (65.3% and 55.6% accuracy, respectively), but their guesses 
exceeded chance (50%). Importantly, though, successful guessing 
did not appear to undermine the internal validity of the trial, 
because accuracy was comparable across drug and placebo condi- 
tions. Fourth, because follow-up extended only to 6 months 
postquit date, it is unknown whether effects persist over the longer 
term. Fifth, because all participants received cognitive-behavioral 
group therapy in addition to fluoxetine or placebo, effects of 
pharmacotherapy alone cannot be discerned. 
Study results extend and clarify previous findings regarding 
influences of SSRIs and depressive history on smoking cessation. 
Past research has yielded mixed findings as to whether serotoner- 
gic agents benefit tobacco abstinence in the short-term. The current 
findings suggest that such benefit does occur initially among 
smokers with a history of depression. In the present study, the 
on-drug advantage for H +  smokers lasted for the first 6 weeks 
postquit. However, such a drug benefit is too transient to be 
clinically useful, especially since fluoxetine has a clinically sig- 
nificant adverse impact on abstinence in the long-term. Fluox- 
etine's longer-term suppression of abstinence contraindicates us- 
ing the drug as a cessation treatment regardless of a patient's 
depressive vulnerability, particularly since there are available 
other, more effective smoking pharmacotherapies with antidepres- 
sant properties (bupropion, nortriptyline). Further study of psycho- 
biological mechanisms is warranted to determine why high-dose 
SSRI treatment apparently produces a continuing effect that op- 
poses tobacco abstinence. 
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